EGFR and head and neck squamous cell carcinoma: Combined targeting approaches were further fuelled by the approval of the anti-EGFR monoclonal antibody (mAb) cetuximab in the curative treatment of HNSCC and by the desire to increase efficacy and repress by-pass signaling and resistance, which pose a potential risk to all signaling inhibition approaches (15).